Q-omics provides the consensus-scored UQCC3 profile across patient tissues and cancer cell-line models. UQCC3 expression is associated with patient survival in 24 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, UQCC3 is differentially expressed in 14, with the highest sampling consensus in BLCA. Additionally, UQCC3 RNA expression shows 18,818 significant gene co-expression associations, with the highest sampling consensus in THYM. Together, these results highlight ACC, BLCA, and THYM as cancer lineages where UQCC3 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for UQCC3 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes UQCC3 survival associations across molecular data types. UQCC3 RNA expression shows survival associations in the most cancer types (24), followed by mutation status (1) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible UQCC3 RNA expression–survival associations across cancer types. High UQCC3 expression shows unfavorable associations in ACC, KICH, LIHC, UVM, MESO and LGG. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for UQCC3 RNA expression.
This table summarizes UQCC3 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 14, while mass-spec protein shows differences in 4. The strongest signals are observed in BLCA for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for UQCC3. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. UQCC3 shows higher tumor expression in BLCA, KIRC, LUAD, STAD, LUSC and LIHC. The BLCA box plot shows higher UQCC3 RNA expression in tumor versus normal tissue (log2 FC = +1.208, t-test p < 0.001).
This table shows molecular features associated with UQCC3 in patient tissues and cancer cell lines. In patient samples, UQCC3 shows the broadest associations at the RNA and protein expression levels, with THYM recurring as the lineage with the largest associated feature set. In cancer cell lines, UQCC3 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in LIVER and BLOOD_Lymphoma.
